Results 251 to 260 of about 68,068 (346)

Lower Podocyte Number per Glomerulus Associates With Progressive CKD. [PDF]

Kidney Int Rep
Denic A, Shaik AA, Fareeduddin SK, Fnu A, Kumar M, Mullan AF, Sharma V, Alexander MP, Pandey A, Wiggins RC, Hodgin JB, Shankland SJ, Rule AD.   +12 more
europepmc   +1 more source

Cystatin C‐based eGFR better predicts renal vancomycin clearance than creatinine‐based eGFR in patients with allogeneic stem cell transplantation

Clinical Pharmacology &Therapeutics, EarlyView.
Knowledge of the glomerular filtration rate (GFR) is mandatory when dosing renally eliminated drugs such as vancomycin. In clinical practice, different biomarkers and various equations are used to estimate GFR (eGFR), resulting in varying estimates.
Eva‐Maria A. Wansing, Sebastian G. Wicha, Peter Bannas, Alexander Heitkamp, Adrin Dadkhah, Nicolaus M. Kröger, Isabel Molwitz, Claudia Langebrake   +7 more
wiley   +1 more source

Type-specific molecular signaling architectures and synaptic plasticity of <i>Drosophila</i> olfactory sensory neurons. [PDF]

Front Cell Neurosci
Acharya N, Wiesel E, Selcho M, Ehmann N, Lamberty M, Hansson BS, Wicher D, Kittel RJ.   +7 more
europepmc   +1 more source

Proses Transmetalasi Gd3+ pada Glomerulus Ginjal: Sebuah Studi Memanfaatkan Monte Carlo Cell [PDF]

Sesilia Shanly Yapary, Adita Sutresno, Jodelin Muninggar   +2 more
openalex   +1 more source

Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
This manuscript describes the scope of implementation and impact of a regulatory agency‐qualified panel of six urine biomarkers on drug development, the process for which was conducted and funded by the Critical Path Institute, the Foundation for the National Institutes of Health, and the United States Food and Drug Administration.
Tanja S. Zabka, Michael Lawton, Tom Chu, Gary S. Friedman, Katrina Peron, Stefan R. Sultana, Warren E. Glaab, Nicholas M. P. King   +7 more
wiley   +1 more source

Hemodynamic simulation and <i>in vitro</i> modeling of three-dimensional glomeruli at anatomical scale. [PDF]

Phys Fluids (1994)
Kim DA, Armenta A, Vaughan JC, Terasaki M, Himmelfarb J, Zheng Y.   +5 more
europepmc   +1 more source

Increased hexokinase II expression in the renal glomerulus of mice in response to arsenic

, 2007
Michele D. Pysher, James Sollome, Suzanne Regan, Trevor R. Cardinal, James B. Hoying, Hilary Brooks, R. Vaillancourt   +6 more
openalex   +1 more source

Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug‐Eluting Stent Implantation

Clinical Pharmacology &Therapeutics, EarlyView.
From the nationwide multicenter consortium, 8,163 patients undergoing drug‐eluting stent implantation were classified according to the presence of the CYP2C19 loss‐of‐function (LoF) allele: rapid or normal metabolizers (RMs/NMs) vs. intermediate or poor metabolizers (IMs/PMs), and clinical risk was stratified using the CHADS‐P2A2RC and TRS 2°P scores ...
Hyun Woong Park, Jae‐Hwan Lee, Jin‐Ok Jeong, Diana A. Gorog, Udaya S. Tantry, Byeong‐Keuk Kim, Hyung Joon Joo, Kiyuk Chang, Jin‐Yong Hwang, Young Bin Song, Sung Gyun Ahn, Jung‐Won Suh, Woong Gil Choi, Jung Rae Cho, Jeehoon Kang, Sang Yeub Lee, Hyo‐Soo Kim, Moo Hyun Kim, Do‐Sun Lim, Eun‐Seok Shin, Paul A. Gurbel, Young‐Hoon Jeong, on behalf of the PTRG‐DES Consortium Investigators   +22 more
wiley   +1 more source

<i>CX3CR1⁺</i> Monocytes/Macrophages Promote Regional Immune Injury in Mesangial Proliferative Glomerulonephritis through Crosstalk with Activated Mesangial Cells. [PDF]

Research (Wash D C)
Zhang J, Fang Q, Huang Y, Qu Y, Liu Q, Li R, Zhou Y, Cui S, Liu R, Wang X, Bai Y, Duan S, Wu L, Chen P, Wang Y, Wu J, Sun X, Cai G, Zheng Y, Hong Q, Chen X.   +20 more
europepmc   +1 more source

Lower Dose‐Normalized Tacrolimus Exposure in CYP3A5*6 vs. *3 Loss‐of‐Function Allele Carriers: A Longitudinal Retrospective Real‐World Study in Kidney Transplant Recipients

Clinical Pharmacology &Therapeutics, EarlyView.
Pharmacogenomic research has historically focused on individuals of European ancestry, leading to the underrepresentation of genetic variants common in non‐European populations. This bias is exemplified by CYP3A5*6, a functionally consequential variant common in individuals of African ancestry (MAF: 11–19%) but virtually absent in Europeans (MAF: 0.15%)
Amar D. Levens, Dirk Jan A. R. Moes, Yanick Boer, Aiko P. J. de Vries, Dorottya K. de Vries, Danny van der Helm, Soufian Meziyerh, Dave L. Roelen, Stefan Böhringer, Teun Van Gelder, Jesse J. Swen   +10 more
wiley   +1 more source